Pharmafile Logo
Pharmafocus logo
Advanced Search

venetoclax

Showing 6 posts of 6 posts found.

nice_reception_2

NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

November 10, 2020
Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …

News
abbvie_0

Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …

News

NICE issues draft guidance rejecting Abbvie’s Venclyxto in chronic lymphocytic leukaemia

October 26, 2018
Medical Communications, Sales and Marketing AbbVie, NHS, NICE, leukaemia, pharma, venetoclax

It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health …

News
abbvie_0

Study shows promise for Venclexta in acute myelogenous leukaemia

August 12, 2016
Research and Development, Sales and Marketing AbbVie, Genentech, Roche, Venclexta, venetoclax

A study published in Cancer Discovery, the journal of the American Association for Cancer Research, suggests that Vencletxa (venetoclax) is …

News
FDA logo

AbbVie/Roche’s venetoclax bags FDA Breakthrough Therapy Designation

January 21, 2016
Sales and Marketing AbbVie, Breakthrough Therapy Designation, FDA, Roche, venetoclax

AbbVie and Roche’s cancer drug venetoclax has been granted Breakthrough Therapy Designation by the FDA in combination with rituximab for …

News

Abbvie and Roche report success in Phase II leukaemia trial

August 13, 2015
Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax

AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024